Trump's Plan on Drug-Pricing Transparency Takes Step Forward - (Bloomberg via NewsPoints Desk)

  • The Office of Management and Budget has received a proposed regulation by the US Department of Health and Human Services (HHS) that deals with drug-pricing transparency in the Medicare and Medicaid systems, reported Bloomberg.

  • The proposal was titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," although little other information was made publicly available.

  • Caitlin Oakley, a spokeswoman for the health agency, said that "while we cannot comment on pending regulations, the president's American Patients First blueprint to lower prescription drug prices and reduce out-of-pocket costs clearly states that HHS is looking at options to require drug-pricing transparency."

  • Released in May, the blueprint states that HHS may make "Medicare and Medicaid prices more transparent, hold drugmakers accountable for their price increases, highlight drugs that have not taken price increases, and recognize when competition is working with an updated drug pricing dashboard."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.